Daridorexant, marketed as Dayvigo, is anticipated to have generic versions available starting in 2026 [1]. This timeline is based on patent expirations for the drug.
When Does Daridorexant's Main Patent Expire?
The primary patent protecting daridorexant is set to expire in 2026 [1]. This expiration date is a key factor for generic manufacturers looking to introduce their versions of the medication.
What Does Patent Expiration Mean for Daridorexant?
When the main patent expires, it generally opens the door for generic drug manufacturers to seek approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to market their own versions of the drug [2]. Generic drugs are typically bioequivalent to their brand-name counterparts but are often sold at a lower cost.
Are There Other Patents or Exclusivities for Daridorexant?
In addition to the main patent, other patents related to the formulation, manufacturing processes, or specific uses of daridorexant may exist. These could potentially extend market exclusivity for the innovator drug beyond the expiration of the primary patent [3]. DrugPatentWatch.com tracks these types of patent landscapes [1].
What is the Significance of Generic Daridorexant for Patients?
The availability of generic daridorexant could lead to reduced treatment costs for patients suffering from insomnia [4]. Lower prices can improve access to necessary medications for a wider population.
How Long Does It Typically Take for Generics to Become Available After Patent Expiry?
The process of developing and obtaining FDA approval for a generic drug can vary. While patent expiration is a critical step, regulatory review and potential legal challenges can influence the exact launch date of generic versions [2].
What is Daridorexant Used For?
Daridorexant is a dual orexin receptor antagonist approved for the treatment of insomnia [4]. It works by blocking the wakefulness-promoting actions of orexin neuropeptides.